Log in

NASDAQ:CERSCerus Stock Price, Forecast & News

-0.04 (-0.62 %)
(As of 06/4/2020 04:00 PM ET)
Today's Range
Now: $6.37
50-Day Range
MA: $5.63
52-Week Range
Now: $6.37
Volume1.44 million shs
Average Volume1.92 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Read More
Cerus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:CERS



Sales & Book Value

Annual Sales$74.65 million
Book Value$0.41 per share


Net Income$-71,240,000.00


Market Cap$1.04 billion
Next Earnings Date8/6/2020 (Estimated)

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock been impacted by COVID-19 (Coronavirus)?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CERS shares have increased by 33.8% and is now trading at $6.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cerus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerus.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Cerus.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.00. The biotechnology company had revenue of $18.61 million for the quarter, compared to the consensus estimate of $17.60 million. Cerus had a negative return on equity of 93.16% and a negative net margin of 90.97%. View Cerus' earnings history.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $111.9 million.

What price target have analysts set for CERS?

3 brokerages have issued 1 year target prices for Cerus' shares. Their forecasts range from $6.50 to $8.00. On average, they anticipate Cerus' share price to reach $7.17 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View analysts' price targets for Cerus.

Has Cerus been receiving favorable news coverage?

Press coverage about CERS stock has trended very negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cerus earned a news impact score of -3.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutCerus.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.63%), Primecap Management Co. CA (6.83%), Nikko Asset Management Americas Inc. (6.53%), Nikko Asset Management Americas Inc. (6.53%), Sumitomo Mitsui Trust Holdings Inc. (6.52%) and State Street Corp (2.47%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View institutional ownership trends for Cerus.

Which major investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Two Sigma Investments LP, Millrace Asset Group Inc., Primecap Management Co. CA, Morgan Stanley, Morgan Stanley, Baird Financial Group Inc., and Two Sigma Advisers LP. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman. View insider buying and selling activity for Cerus.

Which major investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including Silvercrest Asset Management Group LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Paradigm Capital Management Inc. NY, First Midwest Bank Trust Division, and Geode Capital Management LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman. View insider buying and selling activity for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.37.

How big of a company is Cerus?

Cerus has a market capitalization of $1.04 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.